Pancreatic Cancer Research

ResearcherSichuan UniversityActive in the last 2 years

Qunli Xiong

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-8319-2834; OpenAlex author ID A5059774216. Sources: OpenAlex.

Their work

Papers
11 (first author 3, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
17
Papers, trials and grants by year

2021: 1 paper · 2022: 3 papers · 2023: 2 papers · 2024: 4 papers · 2025: none · 2026: 1 paper

Papers 11

  1. circPLEKHM1 promotes tumor growth and metastasis through enhancing FXR1-mediated protein translation in PDAC. Co-author DOI 10.1016/j.canlet.2026.218414↗
  2. Identified γ-glutamyl cyclotransferase (GGCT) as a novel regulator in the progression and immunotherapy of pancreatic ductal adenocarcinoma through multi-omics… First author DOI 10.1007/s00432-024-05789-0↗
  3. tiRNA-Val-CAC-2 interacts with FUBP1 to promote pancreatic cancer metastasis by activating c‑MYC transcription. Co-author DOI 10.1038/s41388-024-02991-9↗
  4. Establishment and Verification of a Novel Gene Signature Connecting Hypoxia and Lactylation for Predicting Prognosis and Immunotherapy of Pancreatic Ductal Ade… Co-author DOI 10.3390/ijms252011143↗
  5. Serum PCSK9 is a novel serological biomarker for the diagnosis and prognosis of pancreatic cancer. Co-author DOI 10.7717/peerj.18018↗
  6. NSD3, a member of nuclear receptor-binding SET domain family, is a potential prognostic biomarker for pancreatic cancer. Co-author DOI 10.1002/cam4.5774↗
  7. The PD-L1 Expression and Tumor-Infiltrating Immune Cells Predict an Unfavorable Prognosis in Pancreatic Ductal Adenocarcinoma and Adenosquamous Carcinoma. First author DOI 10.3390/jcm12041398↗
  8. Serum Nardilysin as a Prognostic Biomarker in Pancreatic Ductal Adenocarcinoma. First author DOI 10.3390/jcm11113101↗
  9. Pancreatic Adenosquamous Carcinoma: A Rare Pathological Subtype of Pancreatic Cancer. Co-author DOI 10.3390/jcm11247401↗
  10. Krüppel-like Factor 6 Suppresses the Progression of Pancreatic Cancer by Upregulating Activating Transcription Factor 3. Co-author DOI 10.3390/jcm12010200↗
  11. Identification of Novel Molecular Therapeutic Targets and Their Potential Prognostic Biomarkers Among Kinesin Superfamily of Proteins in Pancreatic Ductal Aden… Co-author DOI 10.3389/fonc.2021.708900↗

Closest collaborators

The 17 strongest of 17 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Qing Zhu · 9 shared papers, 2021–2026 · strength 1.80
  2. Yongfeng Xu · 8 shared papers, 2021–2024 · strength 1.49
  3. Zhiwei Zhang · 6 shared papers, 2022–2024 · strength 1.19
  4. Ying Zheng · 3 shared papers, 2022–2024 · strength 0.62
  5. Jinlu Liu · 3 shared papers, 2022–2024 · strength 0.49
  6. Zhu Zeng · 2 shared papers, 2023–2024 · strength 0.36
  7. Ying Zheng · 1 shared paper, 2024 · strength 0.28
  8. Qing Zhu · 1 shared paper, 2024 · strength 0.28
  9. Ningna Weng · 2 shared papers, 2021–2022 · strength 0.27
  10. Ying Cao Xu · 1 shared paper, 2024 · strength 0.26
  11. Y. Yang · 1 shared paper, 2026 · strength 0.25
  12. Yong Peng · 1 shared paper, 2026 · strength 0.25
  13. Xiaojuan Yang · 1 shared paper, 2026 · strength 0.25
  14. Qing Zhu · 1 shared paper, 2022 · strength 0.22
  15. Congya Zhou · 1 shared paper, 2023 · strength 0.18
  16. Yang Yang · 1 shared paper, 2023 · strength 0.18
  17. Yang Yang · 1 shared paper, 2021 · strength 0.12

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.